Scarica l'app Stockscreener
44.49
0.18%
0.08
Dopo l'orario di chiusura:
44.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$44.41
Aprire:
$44.35
Volume 24 ore:
644.80K
Relative Volume:
0.56
Capitalizzazione di mercato:
$2.76B
Reddito:
$45.48M
Utile/perdita netta:
$169.95M
Rapporto P/E:
16.98
EPS:
2.62
Flusso di cassa netto:
$230.85M
1 W Prestazione:
+3.54%
1M Prestazione:
-2.86%
6M Prestazione:
+8.22%
1 anno Prestazione:
+39.29%
Intervallo 1D:
$44.11
$45.20
Intervallo di 1 settimana:
$43.20
$45.83
Portata 52W:
$27.00
$60.60
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Confronta PTGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
44.49 | 2.66B | 45.48M | 169.95M | 230.85M | 2.62 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Therapeutics Insiders Sold US$5.1m Of Shares Suggesting Hesitancy - simplywall.st
HC Wainwright Brokers Reduce Earnings Estimates for PTGX - Defense World
Q2 Earnings Estimate for PTGX Issued By HC Wainwright - Defense World
Protagonist Therapeutics (PTGX) Reveals Promising Phase 3 Trial Results | PTGX Stock News - GuruFocus
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study - Benzinga
Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study - marketscreener.com
J&J posts late-stage data for plaque psoriasis drug (JNJ:NYSE) - Seeking Alpha
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting - Stock Titan
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 - ACCESS Newswire
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - Yahoo Finance
Protagonist Therapeutics: Strategic Advances and Promising Pipeline Drive Buy Rating - TipRanks
Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience - insights.citeline.com
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
Protagonist Therapeutics: Q1 Earnings Snapshot - CTPost
Protagonist Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Protagonist (PTGX) Reports Q1 Revenue Below Expectations While A - GuruFocus
Protagonist (PTGX) Reports Q1 Revenue Below Expectations While Advancing Drug Pipeline | PTGX Stock News - GuruFocus
Protagonist Therapeutics, Inc SEC 10-Q Report - TradingView
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update | PTGX Stock News - GuruFocus
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist Hits Major Clinical Win: Phase 3 Trial Success Sets Stage for Two FDA Filings in 2025 - Stock Titan
Envestnet Asset Management Inc. Lowers Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference - ACCESS Newswire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Mariner LLC - Defense World
Wells Fargo & Company MN Raises Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $65.44 - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Daily Progress: Protagonist Therapeutics Inc (PTGX) Drop -2.84, Closing at 44.85 - DWinneX
Bank of Montreal Can Increases Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 | PTGX Stock News - GuruFocus
Protagonist Therapeutics CFO Sells Shares to Cover Tax Obligation - TradingView
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 - Eagle-Tribune
Major Clinical Breakthrough: Rusfertide Phase 3 PV Treatment Data Earns Coveted ASCO Plenary Spot - Stock Titan
Cerity Partners LLC Sells 1,185 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Legal & General Group Plc Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
When the Price of (PTGX) Talks, People Listen - news.stocktradersdaily.com
Protagonist Therapeutics Reports Granting of Inducement Award | - GuruFocus
Protagonist Therapeutics Reports Granting of Inducement Award - guardonline.com
Protagonist Awards 20,000 Stock Options to Key New Hire at $46.95 - Stock Titan
Alliancebernstein L.P. Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
The 4.2% return this week takes Protagonist Therapeutics' (NASDAQ:PTGX) shareholders five-year gains to 558% - simplywall.st
Geode Capital Management LLC Buys 2,366 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX - Benzinga
Polycythemia Vera Market to Show Remarkable Growth Trends from - openPR.com
BTIG maintains Buy on Protagonist Therapeutics stock, $82 target By Investing.com - Investing.com Canada
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study - Benzinga
Protagonist Therapeutics (PTGX) Unveils Promising Data for Psori - GuruFocus
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Protagonist Therapeutics Inc Azioni (PTGX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ali Asif | Chief Financial Officer |
Apr 22 '25 |
Sale |
46.00 |
1,756 |
80,776 |
61,065 |
| Waddill William D. | Director |
Mar 17 '25 |
Sale |
54.25 |
4,000 |
217,000 |
13,130 |
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):